Feng Wen: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Yu Yang: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Pengfei Zhang: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Jian Zhang: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Jing Zhou: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Ruilei Tang: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Hongdou Chen: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
Hanrui Zheng: b West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University ; Chengdu , China.
Ping Fu: b West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University ; Chengdu , China.
Qiu Li: a Department of Medical Oncology ; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University ; Chengdu , China.
The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose a considerable health burden on patients and society. Hence the study was aimed to assess the cost-effectiveness of RAS screening before monoclonal antibodies (mAbs) therapy based on FIRE-3 study. Four groups were analyzed: group 1, patients with KRAS testing treated with Cmab and FOLFIRI; group 2, patients with RAS testing treated with Cmab and FOLFIRI; group 3, patients with KRAS testing treated with bevacizumab(Bmab) and FOLFIRI; group 4, patients with RAS testing treated with Bmab and FOLFIRI. A Markov model comprising 3 health states (progression-free survival, progressive disease and death) was built. The costs were calculated from a Chinese payer perspective, and survival was reported in quality-adjusted life-months (QALMs). Average total lifetime costs ranged from $104,682.44 (RAS-Bmab) to $136,867.44 (RAS-Cmab), while the survival gained varied from 16.88 QALMs in RAS-Bmab to 21.85 QALMs in RAS-Cmab. The cost per QALM was $6,263.86 for RAS-Cmab, $6,145.84 for KRAS-Bmab, $6,201.57 for RAS-Bmab and $6,960.70 for KRAS-Cmab respectively. The KRAS-Cmab strategy was dominated by the other 3 groups. The first-treatment cost of RAS-Cmab was the most influential one to the model. In all, the RAS screening prior to Cmab treatment in mCRC seems to be a cost-effective strategy in the time of monoclonal antibodies (mAbs) therapy with the most gained QALMs.
